Using machine learning to predict radiation pneumonitis in patients with stage I non-small cell lung cancer treated with stereotactic body radiation therapy

被引:74
|
作者
Valdes, Gilmer [1 ]
Solberg, Timothy D. [1 ]
Heskel, Marina [1 ]
Ungar, Lyle [2 ]
Simone, Charles B., II [1 ]
机构
[1] Univ Penn, Dept Radiat Oncol, Perelman Ctr Adv Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Dept Comp & Informat Sci, 200 S 33Rd St, Philadelphia, PA 19104 USA
来源
PHYSICS IN MEDICINE AND BIOLOGY | 2016年 / 61卷 / 16期
关键词
radiation pneumonitis; stereotactic body radiation therapy (SBRT); non-small cell lung cancer; machine learning; Decision Trees; RUSBoost; Random Forests; DOSE-VOLUME HISTOGRAM; INDUCED PULMONARY TOXICITY; RADIOTHERAPY OUTCOMES; RISK;
D O I
10.1088/0031-9155/61/16/6105
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
To develop a patient-specific 'big data' clinical decision tool to predict pneumonitis in stage I non-small cell lung cancer (NSCLC) patients after stereotactic body radiation therapy (SBRT). 61 features were recorded for 201 consecutive patients with stage I NSCLC treated with SBRT, in whom 8 (4.0%) developed radiation pneumonitis. Pneumonitis thresholds were found for each feature individually using decision stumps. The performance of three different algorithms (Decision Trees, Random Forests, RUSBoost) was evaluated. Learning curves were developed and the training error analyzed and compared to the testing error in order to evaluate the factors needed to obtain a cross-validated error smaller than 0.1. These included the addition of new features, increasing the complexity of the algorithm and enlarging the sample size and number of events. In the univariate analysis, the most important feature selected was the diffusion capacity of the lung for carbon monoxide (DLCO adj%). On multivariate analysis, the three most important features selected were the dose to 15 cc of the heart, dose to 4 cc of the trachea or bronchus, and race. Higher accuracy could be achieved if the RUSBoost algorithm was used with regularization. To predict radiation pneumonitis within an error smaller than 10%, we estimate that a sample size of 800 patients is required. Clinically relevant thresholds that put patients at risk of developing radiation pneumonitis were determined in a cohort of 201 stage I NSCLC patients treated with SBRT. The consistency of these thresholds can provide radiation oncologists with an estimate of their reliability and may inform treatment planning and patient counseling. The accuracy of the classification is limited by the number of patients in the study and not by the features gathered or the complexity of the algorithm.
引用
收藏
页码:6105 / 6120
页数:16
相关论文
共 50 条
  • [41] OUTCOMES OF STEREOTACTIC BODY RADIATION THERAPY FOR STAGE I NON-SMALL CELL LUNG CANCER AND PULMONARY METASTASES.
    Hegi-Johnson, Fiona
    Lam, Johnson
    Gebski, Val
    Eade, Thomas
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S541 - S541
  • [42] Predictors of Distant Recurrence Following Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer
    Wong, Jessica Karen
    Shaikh, Talha
    DeMora, Lyudmila
    Zhang, Eddie
    Borghaei, Hossein
    Hayes, Shelly B.
    Kumar, Sameera
    Meyer, Joshua E.
    Hallman, Mark A.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2020, 43 (04): : 243 - 248
  • [43] Stereotactic body radiation therapy mitigates radiation induced lymphopenia in early stage non-small cell lung cancer
    McLaughlin, Mark F.
    Alam, Morshed
    Smith, Lynnette
    Ryckman, Jeffrey
    Lin, Chi
    Baine, Michael J.
    PLOS ONE, 2020, 15 (11):
  • [44] The Effect of Biologically Effective Dose and Radiation Treatment Schedule on Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy
    Stahl, John M.
    Ross, Rudi
    Harder, Eileen M.
    Mancini, Brandon R.
    Soulos, Pamela R.
    Finkelstein, Steven E.
    Shafman, Timothy D.
    Dosoretz, Arie P.
    Evans, Suzanne B.
    Husain, Zain A.
    Yu, James B.
    Gross, Cary P.
    Decker, Roy H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (05): : 1011 - 1020
  • [45] Safety of stereotactic ablative body radiation for ultracentral stage I non-small cell lung cancer
    Wu, Abraham J. G-Ching
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 : S135 - S138
  • [46] Risk of Pneumonitis After Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer in Patients With Prior Anatomic Resection
    Hayes, J. T.
    Chen, A. M.
    Daly, M. E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S662 - S662
  • [47] A RETROSPECTIVE STUDY OF STEREOTACTIC BODY RADIATION THERAPY FOR STAGE I NON SMALL CELL LUNG CANCER
    Lennerts, E.
    Verboven, K.
    Ninane, C.
    Baudoux, A.
    Bolly, A.
    Bustin, F.
    Closon, M. T.
    Duplaquet, F.
    Gustin, M.
    Maisin, F.
    Vancutsem, O.
    Vandermoten, G.
    Remouchamps, V.
    RADIOTHERAPY AND ONCOLOGY, 2010, 96 : S338 - S338
  • [48] Cardiac Radiation Dose Distribution and Cardiotoxicity in Early-Stage Non-small Cell Lung Cancer Treated with Stereotactic Body Radiation Therapy
    Reshko, L. B.
    Kalman, N. S.
    Hugo, G. D.
    Weiss, E., Jr.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E492 - E492
  • [49] Synchronous Non-Small Cell Lung Cancer Nodules Treated with Stereotactic Body Radiation Therapy (SBRT)
    Kumar, M. S.
    Videtic, G. M. M.
    Woody, N.
    Djemil, T.
    Stephans, K. L.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S227 - S227
  • [50] Trends in stereotactic body radiation therapy for stage I small cell lung cancer
    Stahl, John M.
    Corso, Christopher D.
    Verma, Vivek
    Park, Henry S.
    Nath, Sameer K.
    Husain, Zain A.
    Simone, Charles B., II
    Kim, Anthony W.
    Decker, Roy H.
    LUNG CANCER, 2017, 103 : 11 - 16